Investigators at Oregon Health & Science University (OHSU) Report Findings in Atopic Dermatitis (Interleukin-1a Inhibitor Bermekimab In Patients With Atopic Dermatitis: Randomized and Nonrandomized Studies).

A study conducted at Oregon Health & Science University (OHSU) investigated the efficacy and safety of bermekimab, a monoclonal antibody, in patients with moderate-to-severe atopic dermatitis (AD). Four phase 2 studies were conducted, but larger controlled studies did not confirm the initial positive results observed in earlier trials. The research concluded that while bermekimab showed potential as a treatment for AD in preclinical and early open-label trials, further research is needed to confirm its effectiveness. The study was funded by Janssen Pharmaceutical Companies of Johnson & Johnson. [Extracted from the article]